Health technology assessment, value-based decision making, and innovation

International Journal of Technology Assessment in Health Care

Volumn 29, Issue 4, 2013, Pages 353-359

  Henshall, Chris ^a   Schuller, Tara ^b  

^a UNIVERSITY OF YORK   (United Kingdom)

^b Health Technology Assessment International Secretariat   (United Kingdom)

Author keywords

Biomedical; Coverage; Decision making; Reimbursement; Social values; Technology assessment

Indexed keywords

BIOMEDICAL EQUIPMENT; DECISION MAKING;

BIOMEDICAL; COVERAGE; REIMBURSEMENT; SOCIAL VALUES; TECHNOLOGY ASSESSMENTS;

HEALTH;

ARTICLE; CAREGIVER; EVIDENCE BASED PRACTICE; HEALTH CARE ORGANIZATION; HEALTH CARE QUALITY; HEALTH TECHNOLOGY ASSESSMENT; HUMAN; LICENSING; MEDICAL DECISION MAKING; MEDICAL DEVICE; PATIENT CARE; PERSONAL VALUE; REIMBURSEMENT; SOCIAL CARE; BIOMEDICAL TECHNOLOGY ASSESSMENT; ECONOMICS; MANAGEMENT; MASS COMMUNICATION; ORGANIZATION; PURCHASING; UNITED STATES;

DECISION MAKING, ORGANIZATIONAL; DIFFUSION OF INNOVATION; HUMANS; POLICY MAKING; REIMBURSEMENT MECHANISMS; TECHNOLOGY ASSESSMENT, BIOMEDICAL; UNITED STATES; VALUE-BASED PURCHASING;

EID: 84889567962     PISSN: 02664623     EISSN: 14716348     Source Type: Journal    
DOI: 10.1017/S0266462313000378     Document Type: Article

References (26)

1. Porter M. What is value in health care? N Engl J Med. 2010;363:2477-2481.
2. Kennedy I. Appraising the value of innovation and other benefits: A short study for NICE, 2009; p.
3. http://www.nice.org.uk/media/98F/5C/KennedyStudyFinalReport.pdf (accessed January 8, 2013).
4. Young PL, Olsen L, McGinnis JM. Value in health care: Accounting for cost, quality, safety, outcomes and innovation. Workshop summary: Roundtable on Value & Science-Driven Health Care. Washington, DC: National Academies Press; 2010.
5. Banta D. What is health technology assessment? Int J Technol Assess Health Care. 2009;25:(Suppl 1);7-9.
6. Health Technology Assessment International (HTAi). Mission, aims & objectives.Available at: http://www.htai.org/index.php?id=427 (accessed March 2013).
7. Health Technology Assessment International (HTAi). About the HTAi Policy Forum. http://www.htai.org/index.php?id=643 (accessed March 2013).
8. Henshall C. The HTAi Policy Forum: promoting public-private sector dialogue on the development and use of HTA in health system decision making. Michael. 2012;9:157-164.
9. HTAi Policy Forum background paper; 2013. http://www.htai.org/fileadmin/ HTAi-Files/Policy-Forum-Public/HTAi-Policy-Forum-Back ground-Paper-2013.pdf (accessed March 2013).
10. Towse A, Barnsley P. Approaches to identifying, measuring and aggregating elements of value. Int J Technol Assess Health Care.
11. Culyer AJ. Deliberative processes. London, UK: Office of HealTheconomics; 2009.
12. Henschke C, Sundmacher L, Busse R. Structural changes in the German pharmaceutical market: Price setting mechanisms based on the early benefit evaluation. Health Policy. 2013;109:263-269.
13. Le service ḿedical rendu (SMR) et l'aḿelioration du service ḿedical rendu (ASMR). http://www.has-sante.fr/portail/jcms/r-1506267/fr/ leservice-medical-rendu-smr-et-lamelioration-du-service-medical-renduasmr? xtmc=&xtcr=1 (accessed April 2013).
14. UK Department of Health. A new value-based approach to the pricing of branded medicines: A consultation. Prepared by Medicines, Pharmacy & Industry Group, Department of Health, 2010. http://webarchive. nationalarchives.gov.uk/20130107105354/http://www.dh.gov.uk/prod-consum-dh/ groups/dh-digitalassets/@dh/@en/documents/digitalasset/dh-122793.pdf (Accessed April 2013);
15. or also see current update on NHS work in this area at http://blogs.bmj.com/bmj/2013/02/14/james-rafteryvalue-based-pricing-equality- effects-and-ways-forward/(accessed April 2013).
16. Dolan JG. Multi-criteria clinical decision support: A primer on the use of multiple criteria decision making methods to promote evidence-based patient-centered healthcare. Patient. 2010;3:229-248.
17. Klemp M, Fronsdal K, Facey K. What principles should govern the use of managed entry agreements? Int J Technol Assess Health Care. 2011;27:77-83.
18. Hutton J, Trueman P, Henshall C. Coverage wiThevidence development: An examination of conceptual and policy issues. Int J Technol Assess Health Care. 2007;23:425-432.
19. Stafinski T, Menon D, McCabe C, Philippon DJ. To fund or not to fund: development of a decision-making framework for the coverage of new health technologies. Pharmacoeconomics. 2011;29:771-780.
20. Redberg RF, Walsh J. Pay now, benefits may follow-the case of cardiac computed tomographic angiography. N Engl J Med. 2008;359:2309-2311.
21. Drummond M, Griffin A, Tarricone R. Economic evaluation for devices and drugs-same or different? Value Health. 2009;12:402-406.
22. The Green Park Collaborative (GPC). http://www.greenparkcollabo rative.org/(accessed Month day, year).
23. Eichler HG, Oye K, Baird LG, et al. Adaptive licensing: Taking the next step in the evolution of drug approval. Nature. 2012;91:426-437.
24. Henshall C, Schuller T, Mardhani-Bayne L. Using health technology assessment to support optimal use of technologies in current practice: the challenge of "disinvestment". Int J Technol Assess Health Care. 2012;28:203-210.
25. Green Park Collaborative Alzheimer's Disease Pilot. http://www. greenparkcollaborative.org/alzheimers-disease-pilot/(accessed Month day, year).
26. European Network for Health Technology Assessment (EUnetHTA) Initiative. http://www.eunethta.eu/(accessed Month day, year).